NP / PA
Roswell Family Care, LLC
Roswell Family Care, LLC was paid $6.29M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
33Billing provider infoROSWELL FAMILY CARE, LLC
ROSWELL, NM 88201
ROSWELL, NM 88201
33aNPI1134499262assigned 01/05/2012
33bProvider typeFamily Nurse Practitioner
28Total paid$6.29M
24GClaims105,031
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Nurse Practitioner providers in New Mexico
Rank by total paid#1 of 73
Median peer was paid$90K
This provider vs. median70×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,862 | $597K | |
| 2019 | 12,902 | $732K | |
| 2020 | 11,734 | $635K | |
| 2021 | 17,666 | $892K | |
| 2022 | 19,406 | $1.17M | |
| 2023 | 17,466 | $1.15M | |
| 2024incomplete | 13,995 | $1.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 22,487 | 21,071 | $2.20M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 19,538 | 18,756 | $1.31M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 6,619 | 6,584 | $670K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 9.0% | 5,992 | 5,923 | $564K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.0% | 10,514 | 10,397 | $376K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 3.5% | 363 | 165 | $220K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.9% | 2,957 | 2,927 | $185K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.3% | 1,207 | 1,153 | $146K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.3% | 8,424 | 8,139 | $145K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.2% | 963 | 954 | $138K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.0% | 3,457 | 3,410 | $124K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 1.7% | 558 | 547 | $105K |
28 more codes
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 3,704 | $18K |
| 81002 | <1% | 6,485 | $12K | |
| 99072 | <1% | 3,649 | $11K | |
| 87806 | <1% | 348 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,484 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 454 | $7K |
| 81025 | <1% | 707 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 304 | $4K |
| 86318 | <1% | 226 | $4K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 51 | $3K |
| 87808 | <1% | 197 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 246 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,126 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 60 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 60 | $2K |
| 87634 | <1% | 24 | $2K | |
| 95117 | <1% | 98 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 117 | $1K |
| 87899 | <1% | 67 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 154 | $831.46 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 504 | $815.91 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 58 | $525.92 |
| 36416 | <1% | 533 | $367.03 | |
| 93000 | <1% | 25 | $362.90 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13 | $239.80 |
| 87905 | <1% | 14 | $161.65 | |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | <1% | 45 | $62.76 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 199 | $7.96 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHEAR, ELIZABETH (OFFICE MANAGER)